Fibrogenesis Biomarkers and Clinical Disease Progression in ADPKD.
Urinary collagen fragments uPRO-C3/Cr and uPRO-C6/Cr are associated with kidney outcomes in ADPKD, but their clinical utility remains to be fully established.
Where it sits
this study against the rest of the lanreotide corpusSummary and findings
This study evaluated the association of collagen fragments with clinical outcomes in 302 patients with autosomal dominant polycystic kidney disease (ADPKD) over a mean follow-up of 2.4 years. The findings indicated that uPRO-C3/Cr and uPRO-C6/Cr were independently associated with kidney outcomes. No therapeutic claims are made regarding lanreotide or other treatments.
Abstract
<h4>Introduction</h4>Fibrogenesis contributes to disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD). In this exploratory study, we evaluated the association of protease-generated circulating and urinary collagen fragments (type III collagen degradation [C3M], type III collagen formation [PRO-C3], and type VI collagen formation [PRO-C6]), reflecting fibrogenesis and fibrolysis, with clinical outcomes in ADPKD.<h4>Methods</h4>We included 302 patients from the DIPAK-1 trial (lanreotide vs. standard treatment), with a mean baseline age of 48.9 ± 7.3 years and estimated glomerular filtration rate (eGFR) of 51.3 ± 11.5 ml/min per 1.73 m<sup>2</sup>. Kidney endpoints were eGFR slope, rapid disease progression (eGFR loss ≥3 ml/min per 1.73 m<sup>2</sup> per year), and a composite kidney endpoint (30% eGFR loss or initiation of kidney replacement therapy). Net benefit analysis was performed to assess clinical utility.<h4>Results</h4>During 2.4 ± 0.4 years of follow-up, mean eGFR slope was -4.02 ± 3.64 ml/min per 1.73 m<sup>2</sup> per year, 190 patients (62.9%) had rapid disease progression, and 87 (28.8%) reached the composite endpoint. After adjustment for sex, baseline age, baseline eGFR, Mayo imaging class (MIC), <i>PKD</i> pathogenic variant and treatment group, uPRO-C3/Cr and uPRO-C6/Cr were independently associated with eGFR slope, rapid disease progression, and the composite endpoint. uPRO-C3/Cr was also associated with HtTKV growth rate. Adding uPRO-C3/Cr or uPRO-C6/Cr improved prediction of rapid disease progression, increasing area under curve (AUC) from 0.78 (95% confidence interval [CI], 0.73-0.86) to 0.79 (95% CI, 0.73-0.86) and 0.80 (95% CI, 0.73-0.86), respectively. Decision curve analysis did not show a meaningful net benefit.<h4>Conclusion</h4>These findings demonstrate that uPRO-C3/Cr and uPRO-C6/Cr were independently associated with kidney outcomes in ADPKD, providing clinical evidence that extracellular matrix (ECM) remodeling is associated with ADPKD disease progression.
Background
This paper addresses the role of fibrogenesis in the progression of autosomal dominant polycystic kidney disease (ADPKD). Prior studies have indicated that extracellular matrix remodeling may be linked to kidney disease progression, but specific biomarkers for this process have not been thoroughly investigated. This study is significant as it explores the association between collagen fragments and clinical outcomes in a population of ADPKD patients.
Methods
The study included 302 patients from the DIPAK-1 trial, with a mean age of 48.9 ± 7.3 years and an estimated glomerular filtration rate (eGFR) of 51.3 ± 11.5 ml/min per 1.73 m². The primary outcomes were eGFR slope, rapid disease progression (defined as eGFR loss ≥3 ml/min per 1.73 m² per year), and a composite kidney endpoint (30% eGFR loss or initiation of kidney replacement therapy). The follow-up duration was 2.4 ± 0.4 years.
Results
The mean eGFR slope was -4.02 ± 3.64 ml/min per 1.73 m² per year. Of the patients, 62.9% experienced rapid disease progression, and 28.8% reached the composite endpoint. After adjustments for various factors, urinary collagen fragments uPRO-C3/Cr and uPRO-C6/Cr were found to be independently associated with eGFR slope and rapid disease progression. The addition of these markers improved the area under the curve (AUC) for predicting rapid disease progression.
Interpretation
The findings suggest that urinary collagen fragments may serve as biomarkers for disease progression in ADPKD, aligning with previous literature on the role of extracellular matrix remodeling. However, while the statistical significance of the associations is noted, the clinical relevance remains uncertain due to the lack of a meaningful net benefit demonstrated in decision curve analysis. The study's exploratory nature and potential confounding factors limit the strength of the conclusions.
Key findings
- Mean eGFR slope was -4.02 ± 3.64 ml/min per 1.73 m² per year.
- 190 patients (62.9%) had rapid disease progression (eGFR loss ≥3 ml/min per 1.73 m² per year).
- 87 patients (28.8%) reached the composite endpoint of 30% eGFR loss or initiation of kidney replacement therapy.
- AUC for prediction of rapid disease progression increased from 0.78 (95% CI, 0.73-0.86) to 0.79 (95% CI, 0.73-0.86) with uPRO-C3/Cr.
- AUC for prediction of rapid disease progression increased to 0.80 (95% CI, 0.73-0.86) with uPRO-C6/Cr.
Limitations
- Exploratory study design.
- Decision curve analysis did not show a meaningful net benefit.
- Potential confounding factors not fully addressed.
- Follow-up duration of 2.4 years may be insufficient for long-term outcomes.